News
Aurobindo Pharma’s Eugia Facility Receives US FDA Warning Letter
Aurobindo Pharma said the warning letter to Unit I of Eugia Pharma Specialities will have no impact on existing supplies to the US market.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Aurobindo Pharma said the warning letter to Unit I of Eugia Pharma Specialities will have no impact on existing supplies to the US market.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
